ArticleInternational journal of molecular sciences2026
Clotrimazole Targets the c-Myc-Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents.
Yasufumi Ito, Kazuki Nakamura, Yurika Nakagawa-Saito, Shuhei Suzuki, Yuta Mitobe, Senri Takenouchi, Keita Togashi, Asuka Sugai, Manabu Seino, Tsuyoshi Ohta and 3 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Yasufumi ItoDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Kazuki NakamuraDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Yurika Nakagawa-SaitoDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.ORCID 0000-0002-9904-8842 Shuhei SuzukiDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.ORCID 0000-0003-1975-0146 Yuta MitobeDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Senri TakenouchiDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.ORCID 0009-0008-6850-8763 Keita TogashiDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Asuka SugaiDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Manabu SeinoDepartment of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Tsuyoshi OhtaDepartment of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Satoru NagaseDepartment of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.ORCID 0000-0001-5212-1128 Chifumi KitanakaDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Masashi OkadaDepartment of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.ORCID 0000-0002-6333-6076 Funding
Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan 23K06689
6 · The paper itselfAbstract
Ovarian cancer stem cells (OvCSCs) are one of the main factors contributing to post-treatment recurrence and the poor prognosis of patients with ovarian cancer. Therefore, the development of therapeutic strategies targeting OvCSCs is needed to improve patient survival. We previously reported the high expression of survivin/
Indexed as
Antineoplastic AgentsClotrimazoleNeoplastic Stem CellsOvarian NeoplasmsProto-Oncogene Proteins c-mycSurvivinCell Line, TumorCell SurvivalFemaleGene Expression Regulation, NeoplasticHumansInhibitor of Apoptosis ProteinsAntineoplastic AgentsBIRC5 protein, humanClotrimazoleInhibitor of Apoptosis ProteinsProto-Oncogene Proteins c-mycSurvivinazolebaculoviral inhibitor of apoptosis repeat-containing 5clear cellendometrioidepithelial ovarian cancer
Identifiers
PMID42511518
PMCPMC13411808
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390